Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,422 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-line setting: an observational study.
Yoshinami T, Nagai SE, Hattori M, Okamura T, Watanabe K, Nakayama T, Masuda H, Tsuneizumi M, Takabatake D, Harao M, Yoshino H, Mori N, Yasojima H, Oshiro C, Iwase M, Yamaguchi M, Sangai T, Kosaka N, Tajima K, Masuda N. Yoshinami T, et al. Among authors: nagai se. Breast Cancer. 2024 Apr 20. doi: 10.1007/s12282-024-01575-5. Online ahead of print. Breast Cancer. 2024. PMID: 38642245
Comparative evaluation of analytical pipelines for illumina short- and nanopore long-read 16S rRNA gene amplicon sequencing with mock microbial communities.
Ota Y, Yasunaga K, Mahazu S, Prah I, Nagai S, Hayashi T, Suzuki M, Yoshida M, Hoshino Y, Akeda Y, Suzuki T, Gu Y, Saito R. Ota Y, et al. Among authors: nagai s. J Microbiol Methods. 2024 Apr 8;221:106929. doi: 10.1016/j.mimet.2024.106929. Online ahead of print. J Microbiol Methods. 2024. PMID: 38599390
The Japanese Breast Cancer Society Clinical Practice Guidelines for Breast Cancer, 2022 Edition: changes from the 2018 edition and general statements on breast cancer treatment.
Yamamoto Y, Yamauchi C, Toyama T, Nagai S, Sakai T, Kutomi G, Yoshimura M, Kawai M, Ohtani S, Kubota K, Nakashima K, Honma N, Yoshida M, Tokunaga E, Taira N, Iwata H, Saji S. Yamamoto Y, et al. Among authors: nagai s. Breast Cancer. 2024 May;31(3):340-346. doi: 10.1007/s12282-024-01566-6. Epub 2024 Apr 3. Breast Cancer. 2024. PMID: 38570435 Free PMC article.
Long-term survival and functional outcomes of laparoscopic surgery for clinical stage I ultra-low rectal cancers located within 5 cm of the anal verge: A prospective phase II trial (Ultimate trial).
Ito M, Tsukada Y, Watanabe J, Fukunaga Y, Hirano Y, Sakamoto K, Hamamoto H, Yoshimitsu M, Horie H, Matsuhashi N, Kuriu Y, Nagai S, Hamada M, Yoshioka S, Ohnuma S, Hayama T, Otsuka K, Inoue Y, Ueda K, Toiyama Y, Maruyama S, Yamaguchi S, Tanaka K, Suzuki M, Naitoh T, Ando K, Watanabe M; Ultimate Trial Group. Ito M, et al. Among authors: nagai s. Ann Surg. 2024 Apr 1. doi: 10.1097/SLA.0000000000006290. Online ahead of print. Ann Surg. 2024. PMID: 38557445
Trastuzumab deruxtecan for human epidermal growth factor receptor 2-low advanced or metastatic breast cancer: recommendations from the Japanese Breast Cancer Society Clinical Practice Guidelines.
Hattori M, Honma N, Nagai S, Narui K, Shigechi T, Ozaki Y, Yoshida M, Sakatani T, Sasaki E, Tanabe Y, Tsurutani J, Takano T, Saji S, Masuda S, Horii R, Tsuda H, Yamaguchi R, Toyama T, Yamauchi C, Toi M, Yamamoto Y. Hattori M, et al. Among authors: nagai s. Breast Cancer. 2024 May;31(3):335-339. doi: 10.1007/s12282-024-01550-0. Epub 2024 Mar 4. Breast Cancer. 2024. PMID: 38433181 Free PMC article.
1,422 results